PPARG and metabolic dysfunction-associated steatohepatitis: Because Pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ agonist, improves insulin sensitivity [8] and it is also effective in controlling liver inflammation in subjects with non-alcoholic steatohepatitis (NASH) [9], it has been used as triple therapy in addition to PEG-interferon-α and ribavirin to treat HCV-infected patients.